EASL-ILC 2019 - 54th International Liver Congress of the European Association for the Study of the Liver
Apr 10 - Apr 14, 2019 | ViennaAustria
LARVOL is not affiliated with 54th International Liver Congress of the European Association for the Study of the Liver and all trademarks, logos, and brand names are property of their respective owners
Showing 51 abstracts linked to Trials
Multicentric prospettive study of validation of angiogenesis-related gene polymorphisms in hepatocellular carcinoma patients treated with sorafenib: Interim analysis of INNOVATE study
Early TIPS with covered stent versus standard treatment for acute variceal bleeding among patients with advanced cirrhosis: A randomised controlled trial
Seladelpar for the treatment of primary biliary cholangitis: Experience with 25 cirrhotic patients
Six month interim results of MSDC-0602K in a large phase 2b NASH study demonstrate significant improvement in liver enzymes and glycemic control (NCT02784444)
Endoscopic duodenal mucosal resurfacing improves hepatic fat fraction, glycemic and lipid profiles in type 2 diabetes
PP100-01 (calmangafodipir) for overdose of paracetamol (The POP trial): Principal results
Prognosis assessment of acute-on-chronic liver failure in patients with hepatitis B virus-related cirrhosis requires specific criteria
Pregabalin for muscle cramps in patients with liver cirrhosis: A randomized, double-blind, placebo-controlled trial
Sustained virologic response in patients with cirrhosis from chronic hepatitis C leads to sustained and long-term improvement of health-related quality of life, fatigue, and work productivity
MSDC-0602K, a PPAR-gamma sparing modulator of the mitochondrial pyruvate carrier, improves NASH outcome in a diet-induced animal model of non-alcoholic steatohepatitis
Lanreotide reduces liver growth in autosomal dominant polycystic kidney disease: Data from a 120-week randomized clinical trial
Faecal microbiota transplantation with tenofovir is superior to tenofovir alone in improving clinical outcomes in acute-on-chronic liver failure due to hepatitis B: An open label randomized controlled trial (NCT02689245)
External validation of an algorithm combining multi-analyte blood tests (FibroTest-LCR1-LCR2) for identifying subjects at risk of hepatocellular carcinoma among patients with chronic liver disease
2D-Shear-Wave elastography predicts survival in advanced chronic liver disease
What are the predictors of impairment of patient-reported outcome in non-alcoholic steatohepatitis?